Cite
HARVARD Citation
Danese, S. et al. (n.d.). P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial. Journal of Crohn's and colitis. pp. S330-S331. [Online].